Skip to main content

Advertisement

SpringerLink
Log in

The EU-regulation on medicinal products for paediatric use

Impacts on child and adolescent psychiatry and clinical research with minors

  • ORIGINAL CONTRIBUTION
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

Background

At present the EU-regulation on medicinal products for paediatric use is in the final legislation phase. The Regulation will bring essential changes to the policy of research with minors, to funding and to regulations of drug development in Europe.

Method

The article analyses contents of the regulation and possible effects on research with and treatment of mentally ill minors.

Results

The regulation seems to be a chance to improve pharmacological treatment for children and bring similar research conditions to Europe as they already exist in the US. Some terms of the regulation must be considered as critical due to vague definitions and ambiguously defined policies in some articles. The designated expert committee will be a powerful institution, but it remains to be seen whether this committee will act in the intended way. It is an existing and real danger that European child and adolescent psychiatry will be neglected by the new regulation, if there is no participation of scientists of this discipline in committees. The regulation makes it necessary for child and adolescent psychiatry to strengthen research in clinical trials and developmental psychopharmacology to get benefits from new legislation and improve health care for mentally ill minors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Notes

  1. Minors are defined as people younger than 18 years. This definition of minors is according to the definition of the EU-regulation, whose defines paediatric population as the population between 0 and 18 years.

References

  1. Baber NS (2005) Tripartite meeting. Paediatric regulatory guidelines: do they help in optimizing dose selection for children? Brit J Clin Pharmacol 59:6660–6662

    Google Scholar 

  2. Bodenheimer T (2000) Uneasy alliance–clinical investigators and the pharmaceutical industry. N Engl J Med 342(20):1539–1544

    Article  PubMed  CAS  Google Scholar 

  3. Bücheler R, Schwab M, Mörike K, Kalchthaler B, Mohr H, Schröder H, Schwoerer P, Gleiter CH (2002) Off-label prescribing to outpatient children. Brit Med J 324:1311–1312

    Article  PubMed  Google Scholar 

  4. Commission of the European Communities (2004) Proposal for a Regulation of the European Parliament and the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (presented by the Commission) {SEC(2004) 1144} COM(2004) 599 final 2004/0217 (COD), Brussels, 29.9.2004

  5. Commission of the European Communities (2005) Amended proposal for a Regulation of the European Parliament and the Council on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/83/EC and Regulation (EC) No 726/2004 (presented by the Commission pursuant to Article 250 (2) of the EC Treaty), COM(2005) 577 final, 2004/0217 (COD), Brussels, 10.11.2005

  6. Commission of the European Communities (2006) Communication from the Commission to the European Parliament pursuant to the second subparagraph of Article 251 (2) of the EC Treaty concerning the common position of the Council with a view to the adoption of a regulation on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004, COM(2006) 118 final, 2004/0217(COD), Brussels, 13.3.2006

  7. Conroy S, Choonara I, et al. (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. Brit Med J 320(7227):79–82

    Article  PubMed  CAS  Google Scholar 

  8. EMEA (2006) Paediatric Working Party (PEG) Work programme for 2006, EMEA/CHMP/406990/2005, http://www.emea.eu.int/pdfs/human/peg/40699005en.pdf (access verified 22 June 2006)

  9. Entorf H, Fegert JM, et al. (2004) Children in need of medical innovation, ZEW Zentrum für Europäische Wirtschaftsforschung GmbH:28

  10. European Commission (2001) Directive 2001/20/EC Official Journal of the European Communities L 121/34

  11. Fegert JM, Kölch M, et al. (2003) Sichere und wirksame Arzneimittel auch für Kinder. Z Rechtspol 36(12):446–450

    Google Scholar 

  12. Food and Drug Administration (2003): Approved moieties to which FDA has granted pediatric exclusivity for pediatric studies under section 505A of the Federal Food, Drug and Cosmetic Act. Available at: http://www.fda.gov/cder/pediatric/exgrant.htm, accessed July 19, 2006

  13. Grieve J, Tordoff J, Reith D, Norris P (2005) Effect of the pediatric exclusivity provision on children’s access to medicines. Brit J Clin Pharmacol 59:(6) 730–735

    Article  Google Scholar 

  14. Ian CK, Wong FMCB, Paramala JS, Macey LM (2004) Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Safety 27(13):991–1000

    Article  Google Scholar 

  15. Insel T, Nakamura (2006) The value and limitations of large practical clinical trials in informing practice: The NIMH Perspective; Program from 46th Annual Meeting NCDEU, Boca

  16. Klein DF (2006) The flawed basis for FDA post-marketing safety decisions: the example of antidepressants and children. Neuropsychopharmacology 31:689–699

    Article  PubMed  Google Scholar 

  17. Knöppel C, Klinger O, Soergel M, Seyberth HW, Leonhardt A (2000) Anwendung von Medikamenten außerhalb der Zulassung oder ohne Zulassung bei Kindern. Monatschr Kinderheilkd 148:904–908

    Article  Google Scholar 

  18. Kölch M, Lippert HD, Fegert JM (2006). Die Auswirkungen der 12. und der 14. Novelle zum AMG auf die Forschung mit Arzneimitteln für Kinder. Eine Übersicht zu den Neuregelungen, Zeitschrift für Kinder- und Jugendpsychiatrie. Z Kinder Jugendpsychiatr 34(2):117–126

    Article  Google Scholar 

  19. Lieberman JA, Stroup TS, et al. (2005) Effectiveness of antipsychotic drugs in patients with schizophrenia (CATIE-study). N Engl J Med 353(12):1209–1223

    Article  PubMed  CAS  Google Scholar 

  20. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. : JAMA. 2004 Aug 18;292(7):807–820

  21. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactive disorder. Arch Gen Psychiatry 56, 1073–1086

    Google Scholar 

  22. Rose K (2005) Better medicines for children- where are we and where do we want to be? Brit J Clin Pharmacol 06/2005 59(6):657

    Article  Google Scholar 

  23. Schubert Silvia, Lippert Hans-Dieter, Fegert Jörg M, Kölch Michael (2006) Industrieunabhängige Forschung an Kindern und die 12. Novelle des Arzneimittelgesetzes Eine Studie zum Vergleich klinischer Prüfungen vor und nach der 12. Novelle des Arzneimittelgesetzes ( = A comparison of industry sponsored and investigator initiated trials in children before and after the 12th amendment of German drug law) Monatschrift Kinderheilkunde (in press)

  24. Seyberth HW (2006) Zukünftige Anforderungen aus pädiatrischer Sicht ( = future requirements on the Regulation – the point of view of paediatrics lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz

  25. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:S693–S695

    Google Scholar 

  26. Sudhop T (2006) Voraussetzungen und Durchführung pädiatrischer klinischer Prüfungen aus Sicht einer Bundesoberbehörde ( = Prerequisities and conduct of clinical trials - the point of view of a regulation authority), lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz

  27. Tan J, Fegert JM (2004) Capacity and competence in child and adolescent psychiatry. Health Care Anal 12(4):285–294

    Article  PubMed  Google Scholar 

  28. Vitiello B, Heiligenstein JH, et al. (2004) The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 56:3–9

    Article  PubMed  Google Scholar 

  29. Werner E. (2006) Europäische Kinderarzneimittelverordnung ( = European Regulation on medicinal products for paediatric use), lecture workshop European Regulation on medicinal products for paediatric use in Germany, impacts on paediatrics in Germany, 25.04.2006, Mainz

  30. Zito JM, Derivan AT, Greenhill L (2004) Making research data available: an ethical imperative demonstrated by the SSRI debacle. J Am Acad Child Adoles Psychiatry 43(5):512–514

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Child and Adolescent Psychiatry/Psychotherapy, University of Ulm, Steinhoevel Str. 5, 89075, Ulm, Germany

    Michael Kölch, Kathlen Schnoor & Jörg M. Fegert

Authors
  1. Michael Kölch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathlen Schnoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg M. Fegert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Kölch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kölch, M., Schnoor, K. & Fegert, J. The EU-regulation on medicinal products for paediatric use. Eur Child Adolesc Psychiatry 16, 229–235 (2007). https://doi.org/10.1007/s00787-006-0594-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-006-0594-8

Keywords

Search

Navigation